Titelia

Holdings of NEXTBio Capital Management LP

21 declared positions · as of Mar 31, 2026

Original filing · Ten largest lines: 77 % of the equity sleeve

Sector breakdown

  • Unattributed 100.0 %

Titelia classification, company by company. The unattributed share stays visible.

Currency breakdown

  • USD 100.0 %

The quoted currency of each line, as declared.

Country breakdown

  • US 88.6 %
  • GB 5.8 %
  • FR 3.8 %
  • KY 1.8 %

Shares computed on the equity sleeve.

RankCountryLinesValueShare
1US18171.9M $88.64 %
2GB111.2M $5.77 %
3FR17.4M $3.82 %
4KY13.4M $1.78 %

Positions

RankCompanySharesValueWeight
1Terns Pharmaceuticals Inc 604,53431.9M $
2Protagonist Therapeutics Inc 229,61924.2M $
3Shattuck Labs Inc 3,149,90720.3M $
4Vor BioPharma Inc 999,96717.8M $
5Compass Pathways plc 2,021,40711.2M $
6Rhythm Pharmaceuticals Inc 126,07811M $
7Palvella Therapeutics Inc 82,68610.3M $
8ZENAS BIOPHARMA INC 426,7368.3M $
9Inventiva SACA 1,333,4847.4M $
10Verastem Inc 1,306,8006.9M $
11ORIC Pharmaceuticals Inc 523,6196.6M $
12Structure Therapeutics Inc 133,2396.4M $
13Vaxcyte Inc 95,2235.5M $
14Cogent Biosciences Inc 131,1885M $
15Compass Therapeutics Inc 848,2044.5M $
16Evommune Inc 184,0634.2M $
17ZAI LAB LTD 183,3623.4M $
18Disc Medicine Inc 52,6553.4M $
19KalVista Pharmaceuticals Inc 131,7962.7M $
20Summit Therapeutics Inc 89,7171.7M $
21Adicet Bio Inc 157,8271.1M $